INT3463

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.39
First Reported 1978
Last Reported 2010
Negated 2
Speculated 0
Reported most in Body
Documents 21
Total Number 23
Disease Relevance 21.10
Pain Relevance 2.93

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

extracellular region (Igfals) cell adhesion (Igfals) nucleus (Igfals)
Anatomy Link Frequency
motor neurons 2
liver 1
spinal cord 1
brain 1
spinal 1
Igfals (Mus musculus)
Pain Link Frequency Relevance Heat
Spinal cord 230 99.62 Very High Very High Very High
Inflammation 160 99.14 Very High Very High Very High
Multiple sclerosis 60 99.00 Very High Very High Very High
Glutamate 143 98.48 Very High Very High Very High
Inflammatory mediators 22 96.72 Very High Very High Very High
Hippocampus 69 94.36 High High
depression 7 91.88 High High
cytokine 43 91.20 High High
Pain 24 90.08 High High
Pyramidal cell 4 88.96 High High
Disease Link Frequency Relevance Heat
Motor Neuron Diseases 1003 100.00 Very High Very High Very High
Disease 592 100.00 Very High Very High Very High
Dementia 49 99.76 Very High Very High Very High
Chronic Fatigue Syndrome 22 99.62 Very High Very High Very High
Neurodegenerative Disease 119 99.36 Very High Very High Very High
INFLAMMATION 253 99.14 Very High Very High Very High
Nerve Degeneration 30 99.04 Very High Very High Very High
Multiple Sclerosis 56 99.00 Very High Very High Very High
Targeted Disruption 198 98.30 Very High Very High Very High
Syndrome 22 96.40 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Ciliary neurotrophic factor (CNTF) is a neuroactive cytokine found in Schwann cells, which seems to be released in response to nerve injury.23 CNTF maintains survival of adult motor neurons and mice lacking the CNTF gene develop mild, progressive motor neuron loss.48 In a recent study, serum level of CNTF was significantly higher in ALS patients than in controls.49 There was no difference between familial and sporadic ALS, and a trend for higher levels was observed in patients with spinal-onset ALS, compared to patients with a bulbar onset of the disease.49 ALS patients in two trials (n = 1,300) were treated with subcutaneous CNTF.50,51 No significant difference in either primary or secondary outcomes was observed between CNTF and placebo groups.50–52 However, a significant increase of the incidence of several adverse events was noted in groups treated with higher doses of CNTF.52 Therefore CNTF can not be considered beneficial for patients with ALS.


Neg (No) Gene_expression (treated) of ALS in spinal associated with nervous system injury, disease, motor neuron diseases and cytokine
1) Confidence 0.39 Published 2009 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2785861 Disease Relevance 0.96 Pain Relevance 0.10
Moreover, the uptake of IgG in multivesicular bodies in endothelial cells in the affected areas of the spinal cord was found in both ALS patients and mice injected with human ALS IgG.
Gene_expression (with) of ALS in endothelial cells associated with motor neuron diseases and spinal cord
2) Confidence 0.35 Published 2007 Journal PLoS ONE Section Body Doc Link PMC2075163 Disease Relevance 1.38 Pain Relevance 0.26
The Draize skin test results showed that SLES again was the least irritating at all concentrations tested and that SLS and ALS along with TEALS and SCMT were the most irritating.
Gene_expression (irritating) of ALS in skin
3) Confidence 0.34 Published 1978 Journal Drug Chem Toxicol Section Abstract Doc Link 755672 Disease Relevance 0.14 Pain Relevance 0.15
Recently, we showed disruption of the BBB and BSCB in areas of motor neuron degeneration in the brain and spinal cord in G93A SOD1 mice modeling ALS at both early and late stages of disease using electron microscopy.
Gene_expression (modeling) of ALS in spinal cord associated with disease, nerve degeneration and spinal cord
4) Confidence 0.30 Published 2007 Journal PLoS ONE Section Abstract Doc Link PMC2075163 Disease Relevance 0.32 Pain Relevance 0.16
In XPCS/XPA and CH/XPA animals, liver IGF-BP3 and ALS mRNA levels were reduced in addition to that of IGF-1, although the reduction in ALS expression in CH/XPA did not meet the criteria for statistical significance (Figure 4C and unpublished data).
Gene_expression (expression) of ALS in liver
5) Confidence 0.28 Published 2006 Journal PLoS Genetics Section Body Doc Link PMC1698946 Disease Relevance 0.38 Pain Relevance 0
In a recent study, a connection between VGLUT2 gene expression and ALS was shown, which specified a role for VGLUT2 in motor neuron survival.
Gene_expression (expression) of ALS in motor neuron associated with motor neuron diseases
6) Confidence 0.25 Published 2010 Journal Upsala Journal of Medical Sciences Section Body Doc Link PMC2853350 Disease Relevance 0.51 Pain Relevance 0.19
Transgenic mice that overexpress the mutant human SOD1 gene (G93A mice) are an animal model of ALS and demonstrate elevations in free radical production [8].
Gene_expression (production) of ALS associated with targeted disruption and motor neuron diseases
7) Confidence 0.23 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2827549 Disease Relevance 1.44 Pain Relevance 0.11
In this way, we generated an ALS mouse model with attenuated VGLUT2-dependent glutamatergic signalling (46).
Gene_expression (generated) of ALS associated with motor neuron diseases
8) Confidence 0.21 Published 2010 Journal Upsala Journal of Medical Sciences Section Body Doc Link PMC2853350 Disease Relevance 1.08 Pain Relevance 0.21
A decrease in glutamatergic signalling could prove beneficial for survival of motor neurons and halting the progression of ALS.
Gene_expression (progression) of ALS in motor neurons associated with motor neuron diseases
9) Confidence 0.21 Published 2010 Journal Upsala Journal of Medical Sciences Section Body Doc Link PMC2853350 Disease Relevance 1.08 Pain Relevance 0.20
Talamantes), anti-ALS (AF1436, R&D Systems), anti-mouse P-Jak2 Tyr1007/1008 (Cell Signalling/Ozyme), anti-?
Gene_expression (anti) of ALS
10) Confidence 0.15 Published 2008 Journal PLoS Biology Section Body Doc Link PMC2573928 Disease Relevance 0.12 Pain Relevance 0.10
Recently, we showed disruption of the BBB and BSCB in areas of motor neuron degeneration in the brain and spinal cord in G93A SOD1 mice modeling ALS at both early and late stages of disease using electron microscopy.
Gene_expression (modeling) of ALS in brain associated with disease, nerve degeneration and spinal cord
11) Confidence 0.10 Published 2007 Journal PLoS ONE Section Abstract Doc Link PMC2075163 Disease Relevance 0.32 Pain Relevance 0.16
may not be critical to ALS pathogenesis as genetic deletion of IL-1?
Gene_expression (pathogenesis) of ALS associated with motor neuron diseases
12) Confidence 0.10 Published 2009 Journal Mol Neurodegener Section Body Doc Link PMC2784760 Disease Relevance 1.21 Pain Relevance 0.21
Sequencing of CHMP2B in 433 ALS cases from the North of England identified 4 cases carrying 3 missense mutations, including one novel mutation, p.Thr104Asn, none of which were present in 500 neurologically normal controls.
Gene_expression (cases) of ALS associated with motor neuron diseases
13) Confidence 0.10 Published 2010 Journal PLoS ONE Section Abstract Doc Link PMC2844426 Disease Relevance 1.36 Pain Relevance 0
Of these 37 had familial ALS (FALS) and were negative for mutations in SOD1, TDP43, FUS/TLS, ANG and VAPB; 356 had classical sporadic ALS with UMN and LMN clinical signs and 40 had ALS with a LMN phenotype throughout the disease course (PMA variant).
Neg (negative) Gene_expression (negative) of ALS associated with disease, spinal muscular atrophy and motor neuron diseases
14) Confidence 0.09 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2844426 Disease Relevance 1.05 Pain Relevance 0
However, dramatic reduction of copper in SOD1 by knocking out the copper chaperon for SOD1 (CCS), or by mutating the copper chelating residues, did not affect ALS progression in vivo [36,48].
Gene_expression (progression) of ALS associated with motor neuron diseases
15) Confidence 0.08 Published 2003 Journal BMC Neurosci Section Body Doc Link PMC169170 Disease Relevance 0.41 Pain Relevance 0
In a series of ALS patients, CSF levels of VIP were found to be significantly lower compared with controls.62 VIP has demonstrated potent effects on neurite outgrowth in spinal cord cultures suggesting its use in treatment of ALS.63 Interestingly Sun and colleagues64 noted impaired VIP receptor (VPAC2) production in activated T cells in MS patients, suggesting transcription irregularity at promoter regions of the VPAC2 gene.
Gene_expression (production) of ALS in T cells associated with multiple sclerosis, motor neuron diseases and spinal cord
16) Confidence 0.07 Published 2009 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2695238 Disease Relevance 1.33 Pain Relevance 0.27
Fronto-temporal dementia (FTD) is a neurodegenerative disease in which a vascular component is suggested and immunoreactivity of Bax, a proapoptotic protein regulated in part by PACAP/VIP in astrocytes, suggests a role for autoimmunity in the pathology of FTD.44 Astrogliosis in FTD corresponds with SPECT hypoperfusion, suggesting that astrocyte disruption may be related to disturbances of cerebral perfusion in FTD.45 Cognitive dysfunction is associated with reduced cerebral blood flow in different types of dementia.46 Moreover VRS dilatation associated with microvessel abnormality may contribute to the diagnosis of vascular dementias.47 Changes in social behavior occur in cerebrovascular comprise and may result from an FTD-like syndrome.48 Similarly, reduction in cortical blood flow has been identified in CFS patients;49,50 however these findings were not replicated in a study of twins with CFS.51 FTD however is recognized in ALS.91
Gene_expression (recognized) of ALS in astrocytes associated with chronic fatigue syndrome, vascular dementia, cognitive disorder, autoimmune disease, dementia, syndrome, neurodegenerative disease and motor neuron diseases
17) Confidence 0.07 Published 2009 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2695238 Disease Relevance 1.61 Pain Relevance 0.03
Furthermore, this deficiency is only observed in spinal motor neurons, whereas upper motor neurons, which also degenerate in ALS, showed unaltered editing levels of GluR-B.
Gene_expression (degenerate) of ALS in upper associated with motor neuron diseases
18) Confidence 0.06 Published 2009 Journal Mol Brain Section Body Doc Link PMC2694175 Disease Relevance 1.53 Pain Relevance 0.12
Amyotrophic lateral sclerosis (ALS)
Gene_expression (sclerosis) of ALS in lateral associated with motor neuron diseases
19) Confidence 0.06 Published 2009 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2785862 Disease Relevance 1.02 Pain Relevance 0.05
The importance of addressing all cell types in ALS therapy
Gene_expression (therapy) of ALS associated with motor neuron diseases
20) Confidence 0.05 Published 2007 Journal BMC Genomics Section Body Doc Link PMC1796866 Disease Relevance 0.81 Pain Relevance 0.07

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox